Daewoong Pharmaceutical and HanAll Biopharma Jointly Invest $1 Million in US Immune Cell Therapy Company

Investment in Alloplex based in Boston... Collaboration on Developing Cancer Immunocyte Therapy

Corporate logos of Daewoong Pharmaceutical, HanAll Biopharma, and Alloplex (Photo by Daewoong Pharmaceutical)

[Asia Economy Reporter Kim Ji-hee] Daewoong Pharmaceutical and HanAll Biopharma announced on the 19th that they have made a joint investment of 1 million dollars in the U.S. new drug development company Alloplex Biotherapeutics. Both companies plan to engage in mid- to long-term cooperation for the development of Alloplex's anticancer immune cell therapy.

Alloplex, based in Boston, USA, is a biotech company with an immune cell therapy platform. It was founded in 2016 by Dr. Frank Boriello, an immunologist from Harvard University with over 20 years of experience in the pharmaceutical industry. The company is developing autologous cell therapies derived from peripheral blood mononuclear cells (PBMC) targeting a wide range of tumors.

Through this investment, Alloplex is expected to accelerate the entry into Phase 1 clinical trials of the immune cell therapy 'SUPLEXA,' planned for the first half of 2022. Immune cell therapy involves extracting a patient's immune cells, enhancing their anticancer ability, and re-injecting them into the body to fight cancer cells. By using the patient's own cells rather than external substances, it minimizes drug side effects without affecting normal cells while maximizing anticancer effects.

Jung Seung-won, CEO of HanAll Biopharma, said, "We are pleased to support the development of Alloplex's anticancer immune cell therapy through this joint investment and to help improve the quality of life for cancer patients," adding, "We will continue to expand open collaboration for the development of innovative therapies." Frank Boriello, CEO of Alloplex, emphasized, "We will lead the clinical trial of SUPLEXA, which will begin in Australia in the first half of next year, to achieve good results and make this a successful collaboration."

This content was produced with the assistance of AI translation services.